0 XP   0   0   0

Khiron Life Sciences Corp
Buy, Hold or Sell?

I guess you are interested in Khiron Life Sciences Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Khiron

Let's start. I'm going to help you getting a better view of Khiron Life Sciences Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Khiron Life Sciences Corp even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Khiron Life Sciences Corp is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Khiron Life Sciences Corp. The closing price on 2022-10-04 was $0.0777 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Khiron Life Sciences Corp Daily Candlestick Chart


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Khiron Life Sciences Corp.

1.1. Profitability

An important factor of a company's health is the profitability.

1.1.1. Net Profit Margin

Measures how much net profit Khiron earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Khiron to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Net Profit Margin of -48.5% means that $[indicator name=netProfitMargin&period=MRQ&percentage=1 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Khiron Life Sciences Corp:

  • The MRQ is -48.5%. The company is making a huge loss. -2
  • The TTM is -199.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-48.5%TTM-199.1%+150.5%
TTM-199.1%YOY-201.8%+2.8%
TTM-199.1%5Y-260.7%+61.6%
5Y-260.7%10Y-260.7%0.0%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-48.5%-0.9%-47.6%
TTM-199.1%0.3%-199.4%
YOY-201.8%0.1%-201.9%
5Y-260.7%-0.9%-259.8%
10Y-260.7%-0.3%-260.4%
1.1.2. Return on Assets

Shows how efficient Khiron is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Khiron to the Drug Manufacturers-Specialty & Generic industry mean.
  • -5.4% Return on Assets means that Khiron generated $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Khiron Life Sciences Corp:

  • The MRQ is -5.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -17.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.4%TTM-17.4%+12.0%
TTM-17.4%YOY-7.7%-9.6%
TTM-17.4%5Y-20.4%+3.0%
5Y-20.4%10Y-20.4%0.0%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.4%0.1%-5.5%
TTM-17.4%0.1%-17.5%
YOY-7.7%-0.1%-7.6%
5Y-20.4%-0.2%-20.2%
10Y-20.4%-0.1%-20.3%
1.1.3. Return on Equity

Shows how efficient Khiron is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Khiron to the Drug Manufacturers-Specialty & Generic industry mean.
  • -7.3% Return on Equity means Khiron generated $-0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Khiron Life Sciences Corp:

  • The MRQ is -7.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -22.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.3%TTM-22.5%+15.3%
TTM-22.5%YOY-9.1%-13.5%
TTM-22.5%5Y-29.1%+6.5%
5Y-29.1%10Y-29.1%0.0%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.3%0.6%-7.9%
TTM-22.5%0.4%-22.9%
YOY-9.1%0.4%-9.5%
5Y-29.1%-0.3%-28.8%
10Y-29.1%0.1%-29.2%

1.2. Operating Efficiency of Khiron Life Sciences Corp.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Khiron is operating .

  • Measures how much profit Khiron makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Khiron to the Drug Manufacturers-Specialty & Generic industry mean.
  • An Operating Margin of -69.7% means the company generated $-0.70  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Khiron Life Sciences Corp:

  • The MRQ is -69.7%. The company is operating very inefficient. -2
  • The TTM is -113.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-69.7%TTM-113.4%+43.6%
TTM-113.4%YOY-196.1%+82.7%
TTM-113.4%5Y-240.8%+127.4%
5Y-240.8%10Y-240.8%0.0%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-69.7%2.5%-72.2%
TTM-113.4%1.6%-115.0%
YOY-196.1%2.7%-198.8%
5Y-240.8%2.0%-242.8%
10Y-240.8%1.3%-242.1%
1.2.2. Operating Ratio

Measures how efficient Khiron is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • An Operation Ratio of 2.17 means that the operating costs are $2.17 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Khiron Life Sciences Corp:

  • The MRQ is 2.171. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.696. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.171TTM2.696-0.525
TTM2.696YOY3.080-0.385
TTM2.6965Y3.690-0.994
5Y3.69010Y3.6900.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1711.497+0.674
TTM2.6961.446+1.250
YOY3.0801.389+1.691
5Y3.6901.370+2.320
10Y3.6901.182+2.508

1.3. Liquidity of Khiron Life Sciences Corp.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Khiron is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A Current Ratio of 2.83 means the company has $2.83 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Khiron Life Sciences Corp:

  • The MRQ is 2.834. The company is able to pay all its short-term debts. +1
  • The TTM is 3.349. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.834TTM3.349-0.515
TTM3.349YOY4.258-0.909
TTM3.3495Y4.576-1.227
5Y4.57610Y4.5760.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8341.902+0.932
TTM3.3491.908+1.441
YOY4.2582.112+2.146
5Y4.5762.173+2.403
10Y4.5761.891+2.685
1.3.2. Quick Ratio

Measures if Khiron is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Khiron to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Quick Ratio of 0.58 means the company can pay off $0.58 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Khiron Life Sciences Corp:

  • The MRQ is 0.577. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.521. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.577TTM0.521+0.056
TTM0.521YOY0.671-0.150
TTM0.5215Y1.353-0.832
5Y1.35310Y1.3530.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5770.667-0.090
TTM0.5210.792-0.271
YOY0.6710.819-0.148
5Y1.3530.838+0.515
10Y1.3530.823+0.530

1.4. Solvency of Khiron Life Sciences Corp.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Khiron assets are financed with debt.

  • Below 1 (100%) is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A Debt to Asset Ratio of 0.26 means that Khiron assets are financed with 25.8% credit (debt) and the remaining percentage (100% - 25.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Khiron Life Sciences Corp:

  • The MRQ is 0.258. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.234. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.258TTM0.234+0.024
TTM0.234YOY0.143+0.090
TTM0.2345Y0.200+0.034
5Y0.20010Y0.2000.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2580.433-0.175
TTM0.2340.425-0.191
YOY0.1430.396-0.253
5Y0.2000.402-0.202
10Y0.2000.404-0.204
1.4.2. Debt to Equity Ratio

Measures if Khiron is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Khiron to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Equity ratio of 34.7% means that company has $0.35 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Khiron Life Sciences Corp:

  • The MRQ is 0.347. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.310. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.347TTM0.310+0.037
TTM0.310YOY0.168+0.142
TTM0.3105Y0.276+0.034
5Y0.27610Y0.2760.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3470.668-0.321
TTM0.3100.677-0.367
YOY0.1680.624-0.456
5Y0.2760.686-0.410
10Y0.2760.705-0.429

2. Market Valuation of Khiron Life Sciences Corp

2. Earnings
2.1. Price to Earnings Ratio

Measures how much money you pays for each share for every $1 in earnings Khiron generates.

  • Above 15 is considered overpriced but always compare Khiron to the Drug Manufacturers-Specialty & Generic industry mean.
  • A PE ratio of -0.55 means the investor is paying $-0.55 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Khiron Life Sciences Corp:

  • The EOD is -0.463. Company is losing money. -2
  • The MRQ is -0.554. Company is losing money. -2
  • The TTM is -1.190. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-0.463MRQ-0.554+0.091
MRQ-0.554TTM-1.190+0.636
TTM-1.190YOY-2.065+0.875
TTM-1.1905Y-2.004+0.814
5Y-2.00410Y-2.0040.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD-0.463-0.010-0.453
MRQ-0.554-0.067-0.487
TTM-1.190-0.006-1.184
YOY-2.065-0.031-2.034
5Y-2.0043.518-5.522
10Y-2.0044.263-6.267
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Khiron.

  • Lower is better
  • A PEG ratio of 1 means the investor is paying a fair price for the stock

Let's take a look of the Price Earnings to Growth Ratio trends of Khiron Life Sciences Corp:

  • The MRQ is -0.024. Very Bad. -2
  • The TTM is 0.030. Very good. +2
Trends
Current periodCompared to+/- 
MRQ-0.024TTM0.030-0.054
TTM0.030YOY0.042-0.012
TTM0.0305Y0.042-0.012
5Y0.04210Y0.0420.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.0240.003-0.027
TTM0.0300.019+0.011
YOY0.0420.024+0.018
5Y0.0420.023+0.019
10Y0.0420.026+0.016

2. Books
2.3. Price to Book Ratio

Measures if the stock price of Khiron is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A PB ratio of 0.66 means the investor is paying $0.66 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Khiron Life Sciences Corp:

  • The EOD is 0.547. Very good. +2
  • The MRQ is 0.655. Very good. +2
  • The TTM is 0.871. Very good. +2
Trends
Current periodCompared to+/- 
EOD0.547MRQ0.655-0.108
MRQ0.655TTM0.871-0.216
TTM0.871YOY0.984-0.113
TTM0.8715Y0.575+0.296
5Y0.57510Y0.5750.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD0.5471.407-0.860
MRQ0.6551.588-0.933
TTM0.8712.019-1.148
YOY0.9842.258-1.274
5Y0.5751.986-1.411
10Y0.5751.531-0.956

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Khiron Life Sciences Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Per Share--0.1420.200-29%0.376-62%0.218-35%0.218-35%
Book Value Per Share Growth---0.022-0.036+61%-0.051+130%0.013-272%0.013-272%
Current Ratio--2.8343.349-15%4.258-33%4.576-38%4.576-38%
Debt To Asset Ratio--0.2580.234+10%0.143+80%0.200+29%0.200+29%
Debt To Equity Ratio--0.3470.310+12%0.168+107%0.276+26%0.276+26%
Dividend Per Share----0%-0%-0%-0%
Eps---0.010-0.042+307%-0.034+230%-0.065+526%-0.065+526%
Eps Growth--23.334-6.264+127%-47.751+305%-21.559+192%-21.559+192%
Gains Per Share---0.022-0.036+61%-0.051+130%0.013-272%0.013-272%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin---0.485-1.991+310%-2.018+316%-2.607+437%-2.607+437%
Operating Margin---0.697-1.134+63%-1.961+181%-2.408+245%-2.408+245%
Operating Ratio--2.1712.696-19%3.080-30%3.690-41%3.690-41%
Pb Ratio0.547-20%0.6550.871-25%0.984-33%0.575+14%0.575+14%
Pe Ratio-0.463+16%-0.554-1.190+115%-2.065+273%-2.004+262%-2.004+262%
Peg Ratio---0.0240.030-178%0.042-156%0.042-156%0.042-156%
Price Per Share0.078-20%0.0930.170-45%0.358-74%0.709-87%0.709-87%
Quick Ratio--0.5770.521+11%0.671-14%1.353-57%1.353-57%
Return On Assets---0.054-0.174+222%-0.077+44%-0.204+278%-0.204+278%
Return On Equity---0.073-0.225+210%-0.091+25%-0.291+300%-0.291+300%
 EOD+2 -1MRQTTM+13 -5YOY+12 -65Y+9 -910Y+9 -9

3.2. Fundamental Score

Let's check the fundamental score of Khiron Life Sciences Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.463
Price to Book Ratio (EOD)Between0-10.547
Net Profit Margin (MRQ)Greater than0-0.485
Operating Margin (MRQ)Greater than0-0.697
Quick Ratio (MRQ)Greater than10.577
Current Ratio (MRQ)Greater than12.834
Debt to Asset Ratio (MRQ)Less than10.258
Debt to Equity Ratio (MRQ)Less than10.347
Return on Equity (MRQ)Greater than0.15-0.073
Return on Assets (MRQ)Greater than0.05-0.054
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Khiron Life Sciences Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.090
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets40,239
Total Liabilities10,363
Total Stockholder Equity29,876
 As reported
Total Liabilities 10,363
Total Stockholder Equity+ 29,876
Total Assets = 40,239

Assets

Total Assets40,239
Total Current Assets21,589
Long-term Assets21,589
Total Current Assets
Cash And Cash Equivalents 5,818
Net Receivables 4,397
Inventory 9,434
Other Current Assets 27
Total Current Assets  (as reported)21,589
Total Current Assets  (calculated)19,676
+/- 1,913
Long-term Assets
Property Plant Equipment 13,691
Goodwill 4,071
Intangible Assets 889
Long-term Assets  (as reported)18,651
Long-term Assets  (calculated)18,651
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,619
Long-term Liabilities1,921
Total Stockholder Equity29,876
Total Current Liabilities
Short Long Term Debt 854
Accounts payable 6,608
Other Current Liabilities 157
Total Current Liabilities  (as reported)7,619
Total Current Liabilities  (calculated)7,619
+/-0
Long-term Liabilities
Other Liabilities 1,255
Long-term Liabilities  (as reported)1,921
Long-term Liabilities  (calculated)1,255
+/- 666
Total Stockholder Equity
Common Stock150,390
Retained Earnings -124,395
Other Stockholders Equity 3,881
Total Stockholder Equity (as reported)29,876
Total Stockholder Equity (calculated)29,876
+/-0
Other
Capital Stock150,390
Common Stock Shares Outstanding 210,417
Net Invested Capital 32,219
Net Tangible Assets 24,917
Net Working Capital 13,147



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
2,345
8,602
18,776
40,349
63,381
100,525
94,449
81,912
70,950
67,272
60,947
73,179
62,918
60,072
66,415
42,274
41,845
40,239
40,23941,84542,27466,41560,07262,91873,17960,94767,27270,95081,91294,449100,52563,38140,34918,7768,6022,345
   > Total Current Assets 
1,847
7,335
16,379
23,934
44,797
60,903
54,475
44,810
35,230
30,123
25,235
36,415
28,301
25,933
32,197
23,774
21,839
21,589
21,58921,83923,77432,19725,93328,30136,41525,23530,12335,23044,81054,47560,90344,79723,93416,3797,3351,847
       Cash And Cash Equivalents 
1,209
6,498
14,698
15,014
12,859
25,693
17,364
9,170
19,238
20,054
14,622
8,172
7,059
8,438
15,423
8,923
5,127
5,818
5,8185,1278,92315,4238,4387,0598,17214,62220,05419,2389,17017,36425,69312,85915,01414,6986,4981,209
       Short-term Investments 
0
0
0
3,950
25,529
30,094
30,455
27,560
5,081
0
0
0
0
0
0
0
0
0
0000000005,08127,56030,45530,09425,5293,950000
       Net Receivables 
238
369
1,247
4,171
5,245
3,208
3,151
4,239
3,811
3,997
4,140
4,583
4,787
4,642
4,082
2,880
4,365
4,397
4,3974,3652,8804,0824,6424,7874,5834,1403,9973,8114,2393,1513,2085,2454,1711,247369238
       Other Current Assets 
400
468
434
0
132
0
39
175
3,556
2,622
2,622
14,278
5,446
918
0
0
0
27
270009185,44614,2782,6222,6223,5561753901320434468400
   > Long-term Assets 
0
0
0
0
18,584
39,622
39,973
37,102
35,720
37,149
35,713
36,764
34,617
34,139
34,217
18,500
20,007
18,651
18,65120,00718,50034,21734,13934,61736,76435,71337,14935,72037,10239,97339,62218,5840000
       Property Plant Equipment 
498
1,264
2,393
9,542
11,784
14,441
14,808
15,859
15,076
15,837
15,160
17,518
15,929
15,659
15,645
13,557
14,814
13,691
13,69114,81413,55715,64515,65915,92917,51815,16015,83715,07615,85914,80814,44111,7849,5422,3931,264498
       Goodwill 
0
0
0
4,636
4,636
23,883
23,908
4,349
3,856
4,015
3,822
4,112
3,763
3,704
3,692
4,075
4,290
4,071
4,0714,2904,0753,6923,7043,7634,1123,8224,0153,8564,34923,90823,8834,6364,636000
       Intangible Assets 
1
3
3
2,084
1,928
1,298
1,258
15,554
16,788
16,278
15,760
15,134
14,925
14,777
14,880
868
903
889
88990386814,88014,77714,92515,13415,76016,27816,78815,5541,2581,2981,9282,084331
       Other Assets 
0
0
0
153
143
0
0
1,340
0
1,020
971
0
0
0
0
0
0
0
00000009711,02001,34000143153000
> Total Liabilities 
1,174
1,866
1,880
14,811
15,491
11,390
11,886
11,873
9,511
9,636
9,759
9,950
7,873
9,171
11,408
8,945
12,329
10,363
10,36312,3298,94511,4089,1717,8739,9509,7599,6369,51111,87311,88611,39015,49114,8111,8801,8661,174
   > Total Current Liabilities 
1,174
1,866
1,880
6,596
9,443
7,739
8,257
8,441
6,782
6,879
7,238
7,342
5,705
7,153
6,516
7,717
8,598
7,619
7,6198,5987,7176,5167,1535,7057,3427,2386,8796,7828,4418,2577,7399,4436,5961,8801,8661,174
       Short-term Debt 
0
0
0
0
0
0
611
0
0
0
0
0
0
0
0
0
0
0
00000000000611000000
       Short Long Term Debt 
0
0
0
156
635
538
611
1,007
979
1,091
1,058
1,078
985
502
738
1,522
2,036
854
8542,0361,5227385029851,0781,0581,0919791,007611538635156000
       Accounts payable 
819
872
1,679
5,988
8,808
7,201
7,646
7,434
5,803
5,788
6,180
6,264
4,720
6,651
5,778
4,308
6,431
6,608
6,6086,4314,3085,7786,6514,7206,2646,1805,7885,8037,4347,6467,2018,8085,9881,679872819
       Other Current Liabilities 
0
0
0
176
0
0
0
0
0
0
0
0
0
0
-1
1,887
131
157
1571311,887-10000000000176000
   > Long-term Liabilities 
0
0
0
0
6,048
3,651
3,629
3,433
2,728
2,757
2,521
2,608
2,167
2,018
4,893
1,228
1,262
1,921
1,9211,2621,2284,8932,0182,1672,6082,5212,7572,7283,4333,6293,6516,0480000
       Other Liabilities 
0
0
0
5,863
4,136
802
409
887
779
804
758
896
838
818
3,696
523
2,978
1,255
1,2552,9785233,6968188388967588047798874098024,1365,863000
> Total Stockholder Equity
1,172
6,736
16,895
25,537
47,890
89,135
82,563
70,039
61,439
57,636
51,188
63,229
55,045
50,901
55,007
33,329
29,516
29,876
29,87629,51633,32955,00750,90155,04563,22951,18857,63661,43970,03982,56389,13547,89025,53716,8956,7361,172
   Common Stock
5,097
11,946
24,807
39,826
69,232
120,529
126,291
121,290
120,758
123,011
123,214
137,081
137,099
139,427
146,332
146,449
146,630
150,390
150,390146,630146,449146,332139,427137,099137,081123,214123,011120,758121,290126,291120,52969,23239,82624,80711,9465,097
   Retained Earnings -124,395-122,224-116,812-97,311-93,973-89,177-83,683-81,309-74,594-68,881-59,964-52,857-42,235-31,590-23,586-17,082-11,901-5,790
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
1,865
6,691
9,170
9,297
10,248
10,842
9,128
8,712
9,562
9,218
9,283
9,831
7,123
5,447
5,985
3,692
5,110
3,881
3,8815,1103,6925,9855,4477,1239,8319,2839,2189,5628,7129,12810,84210,2489,2979,1706,6911,865



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue12,795
Cost of Revenue-6,424
Gross Profit6,3716,371
 
Operating Income (+$)
Gross Profit6,371
Operating Expense-32,582
Operating Income-19,787-26,211
 
Operating Expense (+$)
Research Development1,216
Selling General Administrative23,989
Selling And Marketing Expenses-
Operating Expense32,58225,205
 
Net Interest Income (+$)
Interest Income-
Interest Expense-445
Net Interest Income-445-445
 
Pretax Income (+$)
Operating Income-19,787
Net Interest Income-445
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-33,594-6,426
EBIT - interestExpense = -20,471
-33,594
-32,684
Interest Expense445
Earnings Before Interest and Taxes (ebit)-20,026-33,149
Earnings Before Interest and Taxes (ebitda)-32,034
 
After tax Income (+$)
Income Before Tax-33,594
Tax Provision--465
Net Income From Continuing Ops-33,129-33,129
Net Income-33,129
Net Income Applicable To Common Shares-33,129
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-13,361445
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
FLUX.NASDAQ
1 minute ago

I found you a Golden Cross on the daily chart of FLUX.NASDAQ.

FLUX.NASDAQ Daily Candlestick Chart
FL.NYSE
1 minute ago

I found you a Golden Cross on the daily chart of FL.NYSE.

FL.NYSE Daily Candlestick Chart
FFIE.NASDAQ
1 minute ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of FFIE.NASDAQ.

FFIE.NASDAQ Daily Candlestick Chart
FCRD.NASDAQ
1 minute ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of FCRD.NASDAQ.

FCRD.NASDAQ Daily Candlestick Chart
FCN.NYSE
1 minute ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of FCN.NYSE.

FCN.NYSE Daily Candlestick Chart
EZGO.NASDAQ
1 minute ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of EZGO.NASDAQ.

EZGO.NASDAQ Daily Candlestick Chart
EVLO.NASDAQ
2 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of EVLO.NASDAQ.

EVLO.NASDAQ Daily Candlestick Chart
EVAX.NASDAQ
2 minutes ago

I found you a Rising Three Methods Candle Pattern on the daily chart of EVAX.NASDAQ.

EVAX.NASDAQ Daily Candlestick Chart
ERIE.NASDAQ
2 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ERIE.NASDAQ.

ERIE.NASDAQ Daily Candlestick Chart
EQOS.NASDAQ
2 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of EQOS.NASDAQ.

EQOS.NASDAQ Daily Candlestick Chart
EPAC.NYSE
2 minutes ago

I found you a Golden Cross on the daily chart of EPAC.NYSE.

EPAC.NYSE Daily Candlestick Chart
ENTA.NASDAQ
3 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of ENTA.NASDAQ.

ENTA.NASDAQ Daily Candlestick Chart
ABBRF.OTCQX
3 minutes ago

I found you a Golden Cross on the daily chart of ABBRF.OTCQX.

ABBRF.OTCQX Daily Candlestick Chart
EM.NASDAQ
3 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of EM.NASDAQ.

EM.NASDAQ Daily Candlestick Chart
ELDN.NASDAQ
3 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of ELDN.NASDAQ.

ELDN.NASDAQ Daily Candlestick Chart
EKSO.NASDAQ
3 minutes ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of EKSO.NASDAQ.

EKSO.NASDAQ Daily Candlestick Chart
DYAI.NASDAQ
3 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of DYAI.NASDAQ.

DYAI.NASDAQ Daily Candlestick Chart
DXF.NYSE MKT
3 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of DXF.NYSE MKT.

DXF.NYSE MKT Daily Candlestick Chart
DXPE.NASDAQ
3 minutes ago

I found you a Death Cross on the daily chart of DXPE.NASDAQ.

DXPE.NASDAQ Daily Candlestick Chart
DWACU.NASDAQ
3 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of DWACU.NASDAQ.

DWACU.NASDAQ Daily Candlestick Chart
DRTT.NASDAQ
3 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of DRTT.NASDAQ.

DRTT.NASDAQ Daily Candlestick Chart
DNA.NYSE
5 minutes ago

I found you a Rising Three Methods Candle Pattern on the daily chart of DNA.NYSE.

DNA.NYSE Daily Candlestick Chart
DGWR.OTCQB
6 minutes ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of DGWR.OTCQB.

DGWR.OTCQB Daily Candlestick Chart
CYDY.OTCQB
6 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of CYDY.OTCQB.

CYDY.OTCQB Daily Candlestick Chart
CYRX.NASDAQ
6 minutes ago

I found you a Death Cross on the daily chart of CYRX.NASDAQ.

CYRX.NASDAQ Daily Candlestick Chart